Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. Sells 9,500 Shares

Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. sold 9,500 shares of the company’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $67.96, for a total transaction of $645,620.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $3,189,770.56. This trade represents a 16.83 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Edwards Lifesciences Stock Performance

EW opened at $69.37 on Friday. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The company has a market cap of $40.78 billion, a price-to-earnings ratio of 9.95, a PEG ratio of 4.82 and a beta of 1.12. The company’s 50 day moving average is $71.74 and its 200 day moving average is $70.33. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, equities research analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Evercore ISI decreased their price objective on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a report on Wednesday, February 12th. Wolfe Research lowered shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. Truist Financial reiterated a “hold” rating and issued a $78.00 price target (up from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Morgan Stanley increased their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 12th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $85.00 price target on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $79.95.

Hedge Funds Weigh In On Edwards Lifesciences

Large investors have recently added to or reduced their stakes in the company. Crowley Wealth Management Inc. purchased a new position in Edwards Lifesciences during the fourth quarter valued at approximately $26,000. Vega Investment Solutions purchased a new position in Edwards Lifesciences during the fourth quarter valued at approximately $27,000. Millstone Evans Group LLC purchased a new position in Edwards Lifesciences during the fourth quarter valued at approximately $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Edwards Lifesciences during the fourth quarter valued at approximately $30,000. Finally, FSA Wealth Management LLC bought a new stake in shares of Edwards Lifesciences during the third quarter valued at approximately $30,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.